Patent ID: 9086418
Filing Date: 2015-07-21
Classification: A61P,G01N

Abstract:
1. A method for treating a subject having active ankylosing spondylitis (AS), said method comprising (a) identifying a subject having active AS; (b) administering 40 mg of adalimumab to the subject; (c) determining a post-treatment level of type II collagen C-telopeptide (CTX-II) in a urine sample(s) obtained from the subject following administration of adalimumab to the subject, wherein the post-treatment level of CTX-II is determined using an antibody that specifically binds to CTX-II in an immunoassay; and (d) administering at least one additional dose of 40 mg of adalimumab to the subject provided that the post-treatment level of CTX-II in the sample(s) obtained from the subject is lower than a known standard level of CTX-II, thereby treating the subject having active AS.